125
Views
13
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Minimal stage IA mycosis fungoides. Results of radiotherapy in 15 patients

, &
Pages 165-168 | Received 03 Sep 2008, Accepted 08 Sep 2008, Published online: 28 Oct 2009
 

Abstract

Background: Mycosis fungoides (MF) minimal disease stage IA, characterized by one or few close lesions (up to four), has been considered a distinct entity with a favourable prognosis, where local treatment such as radiotherapy could afford long-lasting remissions. Objective: To review our experience in radiologic treatment of this subset of the disease and compare our results with those reported in the literature. Methods: Fifteen patients presenting with MF minimal disease were treated with localized superficial X-ray therapy, with a total median dose of 22 Gy. Results: At 1 month from the end of radiotherapy, complete remission was observed in 95.45% of irradiation fields and partial remission in 4.54%. The 5-year local progression-free rate was 93.75%, while the overall relapse-free rate at 5 and 10 years was 51%. Conclusions: After an excellent response to radiotherapy, MF minimal disease may experience local or distant failures, even after years. The identification of an optimal dose of radiation and the collection of more cases would be useful in giving new guidelines in the treatment of this subset of the disease.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.